Remote Buying of Acorda Therapeutics Inc through IEX is under development on ETFS.com.
Notify Me when it is readyRemote Selling of Acorda Therapeutics Inc through IEX is under development on ETFS.com.
Notify Me when it is ready- Open
- Previous Close
- Bid
- Ask
- Day Range -
- 52 Week Range -
- Volume
- Avg. Volume
- Volume to USD
- Market Cap
- Beta
- PE Ratio
- Latest EPS
- EPS TTM
- Dividend
- Dividend Yield
- Ex-Dividend Date
- Revenue TTM
- Revenue per Share
- Revenue per Employee
- Profit Margin
- Gross Profit TTM
- Total Cash TTM
- Total Debt TTM
- Shares Outstanding
- Float
- Short Interest
- Short Ratio
- Insider Ownership
- Institution Ownership
Horizon Therapeutics Public Limited (NASDAQ:HZNP) Shares Bought by Wedbush Securities Inc. via ETF Daily News
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Update via ETF Daily News
Acer Therapeutics Inc. (NASDAQ:ACER) Short Interest Down 24.6% in June via ETF Daily News
Short Interest in Addex Therapeutics Ltd (NASDAQ:ADXN) Increases By 29.2% via ETF Daily News
Candel Therapeutics (NASDAQ:CADL) versus Fusion Pharmaceuticals (NASDAQ:FUSN) Head-To-Head Review via ETF Daily News
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Recommendation of “Hold” by Brokerages via ETF Daily News
TRACON Pharmaceuticals (NASDAQ:TCON) and SpringWorks Therapeutics (NASDAQ:SWTX) Head to Head Review via ETF Daily News
Head-To-Head Review: Axsome Therapeutics (NASDAQ:AXSM) and Enlivex Therapeutics (NASDAQ:ENLV) via ETF Daily News
StockNews.com Initiates Coverage on Galectin Therapeutics (NASDAQ:GALT) via ETF Daily News
Koshinski Asset Management Inc. Has $449,000 Stock Holdings in Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) via ETF Daily News
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda's innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.
Analysis is available when the exchange & market are open.